All News
The RheumNow Week in Review - 2 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes rising epidemiologic numbers, vaccine updates for H.
Read Article
ESRD Death Declines in Vasculitis Patients
In the past 2 decades, mortality from end-stage renal disease (ESRD) among U.S. patients with granulomatosis with polyangiitis (GPA) has declined significantly, a nationwide study found.
Read Article
Higher Fracture Risk with PMR and GCA
Corticosteroid therapy is integral to the treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) and a new retrospective cohort study from the UK shows that PMR and GCA have similar, increased risk of fractures.
Read Article
The RheumNow Week in Review - 26 January 2018
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report covers the price of biologics treatment in psoriasis, comorbidities in myositis, bronchiectasis with MPO antibodies, and the risk of secondary TNF failure with anti-drug antibodies.
Read Article
The RheumNow Week in Review - 12 January 2018
Dr. Jack Cush reviews a dozen highlights from the past week on RheumNow.com.
Read Article
Registry Efficacy of Rituximab in Refractory SLE
Despite large randomized trials failing to show the efficacy of RTX in SLE (LUNAR, EXPLORER), uncontrolled observational data suggests possible efficacy and safety of RTX in refractory SLE.
Read Article
Advantages of Intravenous Pulse Cyclophosphamide in ANCA-associated Vasculitis
Researchers from the Nottingham University Hospitals have analyzed the efficacy and safety of oral (PO) and intravenous (IV) cyclophosphamide (CTX) in ANCA-associated vasculitis (AAV) patients and demonstrated a trend for fewer relapses, better 1 year survival and less toxicity w
Read Article
The RheumNow Week in Review - 15 December 2017
Dr. Jack Cush reviews the news from the past week on RheumNow.com. Subscribe to the podcast on iTunes and SoundCloud.com.
Read Article
FDA Approves Mepolizumab for Churg-Strauss (EGPA)
The Food and Drug Administration (FDA) approved use of Nucala (mepolizumab) for use in treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss vasculitis. This is first FDA-approved therapy specifically to treat EGPA.
Read Article
The RheumNow Week in Review - 17 November 2017
Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com. This week he covers FDA warnings on gout drugs, steroid use in Australia, biosimilars lost savings and methotrexate hepatotoxicity in psoriatic arthritis (PsA).
Read Article
The ACR17 RheumNow Week in Review - 10 November 2017
This special edition of the RheumNow Week in Review covers highlights of selected sessions from the 2017 ACR annual meeting in San Diego. Dr.
Read Article
ACR 2017 - Day 2 Highlights
In the afternoon on Monday, the ACR ran a clinical symposium on gout. One presentation stood out, on “Asymptomatic hyperuricemia” (AH) by M. Pillinger, MD from NYU Medical School. At issue is when should AH be treated.
Read Article
RABBIT Risk Scores are Higher in ICU-Admitted RA Patients
The German Rheumatoid Arthritis Biologics Registry (RABBIT) has developed an infectious risk calculator that can project a patient's risk of serious infection in the next 6 months based on several key factors - age, Prior DMARDs, prednisone dose, comorbidities and the biologic intended for use.&n
Read Article
The RheumNow Week in Review - 20 October 2017
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses presentations from APLAR 2017 in Dubai, Catastrophic APS, safety of low-dose prednisone, frequency of psoriatic arthritis and a new drug for PsA and a hepatitis A outbreak in San Diego.
Read Article
Novel Gel Drug Delivery Developed for Rheumatoid Arthritis
Scientists at the Institute for Basic Science have invented a hydrogel capable of delivering drug at sites of inflammation in disorders such as rheumatoid arthritis.
Read Article
Zilretta - a New Drug FDA Approved for Osteoarthritis of the Knee
Flexion Therapeutics announced friday that the U.S. Food and Drug Administration (FDA) has approved its osteoarthritis (OA) of the knee injectable steroid drug Zilretta with the indication of moderate-to-severe knee pain.
Read Article
22 September 2017 The RheumNow Week in Review
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses survey results on membranous nephritis and patient perceptions of steroids, nonadherence, celebrity arthritis and IgG4 treatment.
Read Article
Half of Takayasu's Arteritis Relapse
A French retrospective study of 318 Takayasu's arteritis (TA) patients shows that 50% of patients will relapse and experience a vascular complication ≤10 years from diagnosis.
Read Article
Duration of Azathioprine Maintenance in AAV Does Not Alter Relapse Rates
A European multicentre study examined whether the duration of azathioprine (AZA) maintenance therapy in ANCA-associated vasculitis patients would influence the relapse rate during long-term follow-up.
Read Article
The RheumNow Week in Review – 11 August 2017
The RheumNow Week in Review caps the week's news every Friday. Dr Jack Cush reviews the news, journal reports and important events from the past week in rheumatology.
Read Article